Despite improvements in surgical techniques, the risk for perioperative bleeding remains significant. Transfusion of allogeneic red blood cells, platelets, and hemostatic factors remains the mainstay of current therapy strategy for management of perioperative bleeding. Transfusions significantly contribute to perioperative adverse events. Pharmacologic strategies to prevent or decrease perioperative bleeding are also important therapeutic approaches to reduce the need for allogeneic transfusions. This article discusses systemic pharmacologic prohemostatic agents (aprotinin, lysine analogues, protamine, desmopressin, and recombinant factor VIIa).
MannucciPM, LeviM.Prevention and treatment of major blood loss.N Engl J Med2007; 356: 2301–11.
2.
SpiessBD, RoystonD, LevyJH.Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes.Transfusion2004; 44: 1143–8.
3.
SpiessBD.Risks of transfusion: outcome focus.Transfusion2004; 44 (12 Suppl): 4S–14S.
4.
SpiessBD.Transfusion of blood products affects outcome in cardiac surgery.Semin Cardiothorac Vasc Anesth2004; 8: 267–81.
KarkoutiK, WijeysunderaDN, YauTM.The independent association of massive blood loss with mortality in cardiac surgery.Transfusion2004; 44: 1453–62.
7.
DespotisGJ, ZhangL, LublinDM.Transfusion risks and transfusion-related pro-inflammatory responses.Hematol Oncol Clin North Am2007; 21: 147–61.
8.
LevyJH, TanakaKA, SteinerME.Evaluation and management of bleeding during cardiac surgery.Curr Hematol Rep2005; 4: 368–72.
9.
Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al.Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline.Ann Thorac Surg2007; 83 (5 Suppl): S27–86.
10.
LevyJH, TanakaKA.The anticoagulated patient: strategies for effective blood loss management.Surgery2007; 142 (4 Suppl): S71–7.
11.
DespotisGJ, GoodnoughLT.Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery.Ann Thorac Surg2000; 70 (2 Suppl): S20–32.
LevyJH.Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation.Am J Health Syst Pharm2005; 62 (12 Suppl): S15–9.
15.
RoystonD, ChhatwaniA.Safety aspects of aprotinin therapy in cardiac surgery patients.Expert Opin Drug Saf2006; 5: 539–52.
16.
LeviM, CromheeckeME, de JongeE.Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.Lancet1999; 354: 1940–7.
SedrakyanA, TreasureT, ElefteriadesJA.Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.J Thorac Cardiovasc Surg2004; 128: 442–8.
19.
ManganoDT, TudorIC, DietzelC.The risk associated with aprotinin in cardiac surgery.N Engl J Med2006; 354: 353–65.
20.
ManganoDT, MiaoY, VuylstekeA.Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.JAMA2007; 297: 471–9.
LeviMM, VinkR, de JongeE.Management of bleeding disorders by prohemostatic therapy.Int J Hematol2002; 76 Suppl 2:139–44.
24.
KikuraM, LevyJH, TanakaKA, RamsayJG.A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery.J Am Coll Surg2006; 202: 216–22.
25.
LaupacisA, FergussonD.Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion (ISPOT) Investigators.Anesth Analg1997; 85: 1258–67.
26.
WellsPS.Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature.Am J Ther2002; 9: 377–88.
LevyJH, AdkinsonNF.Anaphylaxis during cardiac surgery: implications for clinicians.Anesth Analg1986; 65: 739–42.
29.
LevyJH, ZaidanJR, FarajB.Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes.Anesth Analg1986; 65: 739–42.
30.
LevyJH, SchwiegerIM, ZaidanJR.Evaluation of patients at risk for protamine reactions.J Thorac Cardiovasc Surg1989; 98: 200–4.
31.
MannucciPM.Treatment of von Willebrand's disease.N Engl J Med2004; 351: 683–94.
MannucciPM.Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.Blood1997; 90: 2515–21.
34.
FedericiAB, MannucciPM.Management of inherited von Willebrand disease in 2007.Ann Med2007; 39: 346–58.
35.
FrankvilleDD, HarperGB, LakeCL, JohnsRA.Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass.Anesthesiology1991; 74: 988–96.
36.
RochaE, LlorensR, PáramoJA.Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?Circulation1988; 77: 1319–23.
37.
SalzmanEW, WeinsteinMJ, ReillyD, WareJA.Adventures in hemostasis. Desmopressin in cardiac surgery.Arch Surg1993; 128: 212–7.
38.
SalzmanEW, WeinsteinMJ, WeintraubRM.Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial.N Engl J Med1986; 314: 1402–6.
39.
WeinsteinM, WareJA, TrollJ, SalzmanE.Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate.Blood1988; 71: 1648–55.
40.
de ProstD, Barbier-BoehmG, HazebroucqJ.Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass.Thromb Haemost1992; 68: 106–10.
41.
MannucciPM, CarlssonS, HarrisAS.Desmopressin, surgery and thrombosis.Thromb Haemost1994; 71: 154–5.
42.
NielsenVG, LevyJH.Fibrinogen and bleeding: old molecule—new ideas.Anesth Analg2007; 105: 902–3.
43.
BlomeM, IsgroF, KiesslingAH.Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery.Thromb Haemost2005; 93: 1101–7.
44.
CharbitB, MandelbrotL, SamainE.The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage.J Thromb Haemost2007; 5: 266–73.
45.
SteinerME, KeyNS, LevyJH.Activated recombinant factor VII in cardiac surgery.Curr Opin Anaesthesiol2005; 18: 89–92.
46.
RobertsHR, MonroeDM, WhiteGC.The use of recombinant factor VIIa in the treatment of bleeding disorders.Blood2004; 104: 3858–64.
47.
ten CateH, BauerKA, LeviM.The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.J Clin Invest1993; 92: 1207–12.
48.
ButenasS, BrummelKE, BrandaRF.Mechanism of factor VIIa-dependent coagulation in hemophilia blood.Blood2002; 99: 923–30.
49.
LevyJH, FingerhutA, BrottT.Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.Transfusion2006; 46: 919–33.
50.
O'ConnellKA, WoodJJ, WiseRP.Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.JAMA2006; 295: 293–8.
51.
GoodnoughLT, LublinDM, ZhangL.Transfusion medicine service policies for recombinant factor VIIa administration.Transfusion2004; 44: 1325–31.
